<DOC>
	<DOCNO>NCT01257360</DOCNO>
	<brief_summary>The objective trial obtain evidence , patient RAS wildtype tumor , chemotherapy-free combined modality treatment panitumumab clearly superior radiotherapy alone achieve pCR rate comparable radiochemotherapy include two-drug combination reduce toxicity compare two-drug regimen .</brief_summary>
	<brief_title>Panitumumab Combination With Radiotherapy Patients With Locally Advanced RAS Wildtype Rectal Cancer ( Clinical Stages II III )</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm diagnosis locally advanced rectal cancer ( stage II III ) localise 0 12 cm ab ano measure rigid rectoscopy ( i.e . low middle third rectum ) Staging requirement : transrectal endoscopic ultrasound ( EUS ) magnetic resonance imaging ( MRI ) Sufficient representative sample material RAS analysis Wildtype RAS ( determine accredit local laboratory , available pathology Mannheim university ) RAS wildtype test KRAS exon 2 ( codon 12/13 ) KRAS exon 3 ( codon 59/61 ) KRAS exon 4 ( codon 117/146 ) NRAS exon 2 ( codon 12/13 ) NRAS exon 3 ( codon 59/61 ) NRAS exon 4 ( codon 117/146 ) Informed consent patient Aged least 18 year WHO Performance Status 02 Life expectancy al least 12 week Adequate haematological , hepatic , renal metabolic function parameter : Leukocytes &gt; 3000/mm³ ANC ≥ 1500/mm³ Platelets ≥ 100,000/mm³ Hb &gt; 9 g/dl Creatinine clearance ≥ 50 ml/min serum creatinine ≤ 1.5 x upper limit normal Bilirubin ≤ 1.5 x upper limit normal GOTGPT ≤ 2.5 x upper limit normal AP ≤ 5 x upper limit normal Magnesium ≥ low limit normal Calcium ≥ low limit normal Lower border tumor localise 12 cm ab ano measure rigid rectoscopy Distant metastases ( exclude CT scan thorax abdomen ) cT4 tumor ( determine MRI and/or endorectal ultrasound ) Risk tumor involvement circumferential resection margin , accord MRI assessment Sphincter spar major reason choose neoadjuvant treatment approach Prior antineoplastic therapy rectal cancer Prior radiotherapy pelvic region Major surgery within last 4 week prior inclusion Subject pregnant breast feeding , plan become pregnant within 6 month end treatment Subject ( male female ) willing use highly effective method contraception ( per institutional standard ) treatment 6 month ( male female ) end treatment ( adequate : oral contraceptive , intrauterine device barrier method conjunction spermicidal jelly ) Serious concurrent disease Ontreatment participation clinical study period 30 day prior inclusion Clinically significant cardiovascular disease ( incl . myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 1 year enrolment History interstitial lung disease , e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan History HIV infection Prior concurrent malignancy ( ≤ 5 year prior enrolment study ) except nonmelanoma skin cancer cervical carcinoma FIGO stage 01 patient continuously diseasefree Known allergic reaction study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>RAS-Wildtype</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Neoadjuvant treatment</keyword>
</DOC>